Everything below concerns cyclic peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.
Even though the original relation was based on studies of spruce, Hankinson's equation has been found to be remarkably accurate for many other types of wood. A generalized form of the Hankinson formula has also been used for predicting the uniaxial tensile strength of wood at an angle to the grain. This formula has the form
from ectoderm (e.g., the epidermis); from endoderm (e.g., the lining of the gastrointestinal tract); from mesoderm (e.g., the inner linings of body cavities). However, pathologists do not consider endothelium and mesothelium (both derived from mesoderm) to be true epithelium. This is because such tissues present very different pathology. For that reason, pathologists label cancers in endothelium and mesothelium sarcomas, whereas true epithelial cancers are called carcinomas. Additionally, the filaments that support these mesoderm-derived tissues are very distinct. Outside of the field of pathology, it is generally accepted that the epithelium arises from all three germ layers.
Lipid profiling is a targeted metabolomics platform that provides a comprehensive analysis of lipid species within a cell or tissue. Profiling based on electrospray ionization tandem mass spectrometry (ESI-MS/MS) is capable of providing quantitative data and is adaptable to high throughput analyses. The powerful approach of transgenics, namely deletion and/or overexpression of a gene product coupled with lipidomics, can give valuable insights into the role of biochemical pathways. Lipid profiling techniques have also been applied to plants and microorganisms such as yeast. A combination of quantitative lipidomic data in conjunction with the corresponding transcriptional data (using gene-array methods) and proteomic data (using tandem MS) enables a systems biology approach to a more in-depth understanding of the metabolic or signaling pathways of interest.
== Scholarly career == Kermani majored in Middle Eastern languages and literature, with minors in philosophy and theater studies, at the University of Cologne, Cairo University, and the University of Bonn. During his semester breaks, he worked as an assistant director and later as a dramaturge at the municipal theaters Schauspiel Frankfurt and Theater an der Ruhr. Kermani wrote his master's thesis in 1993 at the University of Bonn (supervisors: Stefan Wild and Monika Gronke) on the persecuted Egyptian Koranic scholar Nasr Hamid Abu Zaid, whom he later met in Cairo and who had a formative impact on Kermani's approach to religious studies. With the support of the Studienstiftung des deutschen Volkes, Kermani wrote a dissertation entitled Gott ist schön (God is Beautiful), again under the supervision of Arabist Stefan Wild and Iranian studies scholar Monika Gronke. Kermani received his doctorate in Middle Eastern languages and literature at the University of Bonn in 1998. In 2006, he completed his postdoctoral dissertation entitled The Terror of God – Attar, Job, and the Metaphysical Revolt. From 2000 to 2003, Kermani held a long-term fellowship at the Wissenschaftskolleg zu Berlin (Institute for Advanced Studies Berlin), where he headed the Modernity and Islam working group. He initiated several international research projects, including the project Jewish and Islamic Hermeneutics as Cultural Criticism. This gave rise to a proposal for a Jewish-Islamic academy in Berlin.
Mass change = (unbound system calculated mass) − (measured mass of system) e.g. (sum of masses of protons and neutrons) − (measured mass of nucleus) After a nuclear reaction occurs that results in an excited nucleus, the energy that must be radiated or otherwise removed as binding energy in order to decay to the unexcited state may be in one of several forms. This may be electromagnetic waves, such as gamma radiation; the kinetic energy of an ejected particle, such as an electron, in internal conversion decay; or partly as the rest mass of one or more emitted particles, such as the particles of beta decay. No mass deficit can appear, in theory, until this radiation or this energy has been emitted and is no longer part of the system. When nucleons bind together to form a nucleus, they must lose a small amount of mass, i.e. there is a change in mass to stay bound. This mass change must be released as various types of photon or other particle energy as above, according to the relation E = mc2. Thus, after the binding energy has been removed, binding energy = mass change × c2. This energy is a measure of the forces that hold the nucleons together. It represents energy that must be resupplied from the environment for the nucleus to be broken up into individual nucleons. For example, an atom of deuterium has a mass defect of 0.0023884 Da, and its binding energy is nearly equal to 2.23 MeV. This means that energy of 2.23 MeV is required to disintegrate an atom of deuterium.
Sources: en.wikipedia.org
== Society and culture == Certain preparations of famotidine are available over-the-counter (OTC) in various countries. In the United States and Canada, 10 mg and 20 mg tablets, sometimes in combination with an antacid, are available OTC. Larger doses still require a prescription. Famotidine is generally restricted to prescription only in the United Kingdom, although the medication is legally allowed to be sold OTC to persons aged over 16 in supplies lasting no more than a fortnight. Formulations of famotidine in combination with ibuprofen were marketed by Horizon Pharma under the trade name Duexis.
=== January === 1 January – A driver runs over two police officers on a foot patrol in Nelson, killing one and injuring the other. A 32-year-old man is arrested. 3 January: A 32-year old man is charged with the murder of Nelson police officer Senior Sergeant Lyn Fleming. Biosecurity New Zealand launches a major biosecurity operation after an oriental fruit fly is detected in South Auckland. Thousands attend a vigil in Nelson for slain police officer Lyn Fleming. Air New Zealand flight NZ677 from Auckland to Dunedin is cancelled due to a phone threat, affecting 170 passengers. 4 January – Interislander and Bluebridge cancel a total of seven ferry crossings in response to rough weather conditions in the Cook Strait. 5 January – Interislander and Bluebridge cancel five ferry crossings in response to continuing rough weather in the Cook Strait. 6 January: The Desert Road closes for two months of repairs. Interislander and Bluebridge suspend ferry crossings due to rough weather in the Cook Strait. 8 January – Over 2,070 customers in the Kaipara District experience internet outages after a digger damages the main fibre optic cable between Whangārei and Dargaville. 9 January: In response to significant public interest, New Zealand Parliament's justice select committee extends the submission deadline for the Treaty Principles Bill to 1pm on 14 January. A fire engulfs 20 hectares (49 acres) of scrubland in Whangārei, leading to the evacuation of two houses.
==== IEC/HIC ==== Since IEC and HIC conditions are the closest ones to physiological conditions which are fit for maintaining biological activity, the combinations of them are widely used in the separation of biological products. IEC/HIC MMC has improved separation power and selectivity on the grounds that it applies both electrostatic and hydrophobic interactions.
1908 saw a boom in the use of radioactive water for therapeutic purposes. The discovery of springs in Oberschlema and Bad Brambach paved the way for the establishment of radium spas, which relied on the healing properties of radium. During the cures, people bathed in radium water, drank cures with radium water, and inhaled radon in emanatoriums. The baths were visited by tens of thousands of people every year, hoping for hormesis. To this day, therapeutic applications are carried out in spas and healing tunnels. The natural release of radon from the ground is used. According to the German Spa Association, the activity in water must be at least 666 Bq/liter. The requirement for inhalation treatments is at least 37,000 Bq/m3 of air. This form of therapy is not scientifically accepted and the potential risk of radiation exposure is criticized. The equivalent dose of a radon cure in Germany is given by the individual health resorts as about one to two millisieverts, depending on the location. In 2010, doctors in Erlangen, using the (outdated) LNT (Linear, No-Threshold) model, concluded that five percent of all lung cancer deaths in Germany are caused by radon.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.